BRPI0416544A - proteìna de ligação de gag - Google Patents
proteìna de ligação de gagInfo
- Publication number
- BRPI0416544A BRPI0416544A BRPI0416544-6A BRPI0416544A BRPI0416544A BR PI0416544 A BRPI0416544 A BR PI0416544A BR PI0416544 A BRPI0416544 A BR PI0416544A BR PI0416544 A BRPI0416544 A BR PI0416544A
- Authority
- BR
- Brazil
- Prior art keywords
- gag binding
- site
- gag
- binding protein
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5421—IL-8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
"PROTEìNAS DE LIGAçãO DE GAG". A presente invenção refere-se a um método que é fornecido para introduzir um sítio de ligação de GAG em uma proteína compreendendo as etapas: - identificar uma região em uma proteína que não seja essencial para a manutenção da estrutura; - introduzir pelo menos um aminoácido básico no dito sítio e/ou suprimir pelo menos um aminoácido volumoso e/ou ácido no dito sítio, com o qual o dito sítio de ligação de GAG tem uma afinidade de ligação de GAG de Kd <243> 10 <109>M, preferivelmente <243> 1 <109>M, ainda preferido <243> 0,1 <109>M, assim como proteínas de ligação de GAG modificadas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT0195203A AT412785B (de) | 2003-12-04 | 2003-12-04 | Gag-bindungsproteine |
PCT/EP2004/013670 WO2005054285A1 (en) | 2003-12-04 | 2004-12-02 | Gag binding proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0416544A true BRPI0416544A (pt) | 2007-01-09 |
Family
ID=33494536
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0416544-6A BRPI0416544A (pt) | 2003-12-04 | 2004-12-02 | proteìna de ligação de gag |
Country Status (20)
Country | Link |
---|---|
US (4) | US7585937B2 (pt) |
EP (5) | EP2270038A3 (pt) |
JP (3) | JP4980721B2 (pt) |
KR (2) | KR101278459B1 (pt) |
CN (1) | CN1890264B (pt) |
AT (3) | AT412785B (pt) |
AU (1) | AU2004295104B2 (pt) |
BR (1) | BRPI0416544A (pt) |
CA (1) | CA2546789A1 (pt) |
CY (2) | CY1109480T1 (pt) |
DE (1) | DE602004022595D1 (pt) |
DK (2) | DK1689775T3 (pt) |
ES (2) | ES2369139T3 (pt) |
IL (1) | IL175565A0 (pt) |
NZ (1) | NZ547612A (pt) |
PL (2) | PL1689775T3 (pt) |
PT (2) | PT1689775E (pt) |
SG (1) | SG149000A1 (pt) |
SI (2) | SI1752470T1 (pt) |
WO (1) | WO2005054285A1 (pt) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT412785B (de) * | 2003-12-04 | 2005-07-25 | Kungl Andreas J Dr | Gag-bindungsproteine |
US8044179B2 (en) * | 2005-09-13 | 2011-10-25 | National Research Council Of Canada | Methods and compositions for modulating tumor cell activity |
CN100366637C (zh) * | 2005-11-17 | 2008-02-06 | 中国人民解放军第四军医大学 | 人白细胞介素8拮抗蛋白及其制备方法 |
US9422356B2 (en) * | 2006-01-31 | 2016-08-23 | Republic Of Korea (Republic Of National Fisheries Research And Development Institute) | Artificial signal peptide for expressing an insoluble protein as a soluble active form |
CA2822302A1 (en) | 2006-02-13 | 2007-08-23 | Alethia Biotherapeutics Inc. | Methods of impairing osteoclast differentiation |
US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
EP1894571A1 (en) * | 2006-08-29 | 2008-03-05 | Protaffin Biotechnologie AG | Use of modified interleukin-8 proteins for treating reperfusion injury or transplant rejection |
US20100075918A1 (en) * | 2006-12-08 | 2010-03-25 | Lokeshwar Vinata B | Hyaluronidase inhibitors as anti-cancer agents |
AT504685B1 (de) * | 2006-12-20 | 2009-01-15 | Protaffin Biotechnologie Ag | Fusionsproteine |
JP2010540410A (ja) * | 2007-05-07 | 2010-12-24 | ペプティミューン,インコーポレイテッド | 抗体リガンドとしての使用のためのエピトープの定方向拡大のための方法 |
EP2042516A1 (en) | 2007-09-27 | 2009-04-01 | Protaffin Biotechnologie AG | Glycosaminoglycan-antagonising MCP-1 mutants and methods of using same |
JP5624884B2 (ja) | 2007-08-02 | 2014-11-12 | ノビミューンエスアー | 抗rantes抗体およびその使用の方法 |
EP2053060A1 (en) * | 2007-10-24 | 2009-04-29 | Protaffin Biotechnologie AG | SDF-1-based glyocosaminoglycan antagonists and methods of using same |
US8314212B2 (en) * | 2008-02-08 | 2012-11-20 | Lindsey Miles | Plasminogen receptor PLG-RKT and antibodies thereof |
JP2012516143A (ja) * | 2009-01-30 | 2012-07-19 | プロットアフィン ビオテヒノロギー アクチエンゲゼルシャフト | グリコサミノグリカンを拮抗するmcp−1突然変異体およびその使用方法 |
WO2011029931A1 (en) | 2009-09-11 | 2011-03-17 | Protaffin Biotechnologie Ag | Composition for treatment of cxcl8-mediated lung inflammation |
AU2010324506B2 (en) | 2009-11-24 | 2015-02-26 | Alethia Biotherapeutics Inc. | Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume |
GB201012603D0 (en) * | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Protein purification |
WO2012123585A1 (en) | 2011-03-16 | 2012-09-20 | Protaffin Biotechnologie Ag | Fgfr1-based antagonists with improved glycosaminoglycan affinity and methods of using same |
WO2013007704A2 (en) | 2011-07-08 | 2013-01-17 | Protaffin Biotechnologie Ag | Novel sdf-1-based glycosaminoglycan antagonist and methods of using same |
US9822170B2 (en) | 2012-02-22 | 2017-11-21 | Alethia Biotherapeutics Inc. | Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer |
MX2015000863A (es) | 2012-07-19 | 2016-05-05 | Alethia Biotherapeutics Inc | Anticuerpos anti-siglec-15. |
WO2014079957A1 (de) * | 2012-11-23 | 2014-05-30 | Bayer Cropscience Ag | Selektive inhibition der ethylensignaltransduktion |
US9493528B2 (en) * | 2013-01-10 | 2016-11-15 | Supadelixir Inc. | Microphthalmia-associated transcription factor-derived peptide and composition containing same |
WO2015110526A1 (en) * | 2014-01-22 | 2015-07-30 | Antagonis Biotherapeutics Gmbh | Novel glycosaminoglycan-antagonising fusion proteins and methods of using same |
WO2021038033A1 (en) | 2019-08-29 | 2021-03-04 | Antagonis Biotherapeutics Gmbh | T-cell mobilizing cxcl10 mutant with increased glycosaminoglycan binding affinity |
CN110791523B (zh) * | 2019-12-13 | 2022-05-10 | 南京农业大学 | 一种棉花抗旱相关基因GhRCHY1及其应用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4960691A (en) * | 1986-09-29 | 1990-10-02 | Abbott Laboratories | Chromatographic test strip for determining ligands or receptors |
US5234911A (en) * | 1990-07-09 | 1993-08-10 | Gist-Brocades, N.V. | Substance with interleukin-8 inhibiting activity and process for its preparation |
AU8947791A (en) * | 1990-11-01 | 1992-05-26 | Scripps Research Institute, The | Glycosaminoglycan-targeted fusion proteins, their design, construction and compositions |
EP0607777B1 (de) * | 1993-01-08 | 1998-12-09 | Hoechst Aktiengesellschaft | Verwendung von Leflunomid zur Hemmung von Interleukin 8 |
JP2694321B2 (ja) * | 1993-03-10 | 1997-12-24 | 大塚製薬株式会社 | インターロイキン−1阻害剤 |
US5527546A (en) * | 1994-08-10 | 1996-06-18 | Bayer Corporation | Human interleukin 6 inhibitor |
US5866402A (en) | 1995-05-05 | 1999-02-02 | Chiron Corporation | Chimeric MCP and DAF proteins with cell surface localizing domain |
JPH1045602A (ja) * | 1996-07-31 | 1998-02-17 | Motoyasu Murakami | ヘリコバクター・ピロリ接着阻害剤またはインターロイキン−8産生阻害剤 |
US6852696B2 (en) * | 1999-03-26 | 2005-02-08 | The University Of Texas System | Inhibitors of glycosaminoglycans |
AU2001288025A1 (en) * | 2000-09-05 | 2002-03-22 | Biosight Ltd. | Peptide conjugated anti-cancer prodrugs |
UA77950C2 (en) * | 2000-10-04 | 2007-02-15 | Applied Research Systems | Use of mutants of cc chemokines for treatment of multiple sclerosis |
GB0110430D0 (en) * | 2001-04-27 | 2001-06-20 | Medical Res Council | Protein variants and uses thereof |
JP2003063980A (ja) * | 2001-08-28 | 2003-03-05 | Noevir Co Ltd | Rantes産生阻害剤 |
US6982170B1 (en) * | 2001-12-17 | 2006-01-03 | Maine Medical Center Research Institute | Compositions, methods and kits relating to thrombin degradation resistant fibroblast growth factor-1 |
JP2003306438A (ja) * | 2002-02-18 | 2003-10-28 | Shiseido Co Ltd | ケモカイン発現阻害剤 |
JP2003267887A (ja) * | 2002-03-15 | 2003-09-25 | Shiseido Co Ltd | ケモカイン発現抑制皮膚外用剤 |
IL164376A0 (en) * | 2002-04-03 | 2005-12-18 | Applied Research Systems | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
CN1665839A (zh) * | 2002-04-10 | 2005-09-07 | 应用研究系统Ars股份公司 | Mcp蛋白质的新型拮抗剂 |
AT412785B (de) * | 2003-12-04 | 2005-07-25 | Kungl Andreas J Dr | Gag-bindungsproteine |
-
2003
- 2003-12-04 AT AT0195203A patent/AT412785B/de not_active IP Right Cessation
-
2004
- 2004-12-02 KR KR1020127011106A patent/KR101278459B1/ko not_active IP Right Cessation
- 2004-12-02 EP EP10180974A patent/EP2270038A3/en not_active Withdrawn
- 2004-12-02 SG SG200809009-4A patent/SG149000A1/en unknown
- 2004-12-02 DE DE602004022595T patent/DE602004022595D1/de active Active
- 2004-12-02 SI SI200431257T patent/SI1752470T1/sl unknown
- 2004-12-02 PL PL04801190T patent/PL1689775T3/pl unknown
- 2004-12-02 CA CA002546789A patent/CA2546789A1/en not_active Abandoned
- 2004-12-02 DK DK04801190.2T patent/DK1689775T3/da active
- 2004-12-02 WO PCT/EP2004/013670 patent/WO2005054285A1/en active Application Filing
- 2004-12-02 AT AT04801190T patent/ATE515269T1/de active
- 2004-12-02 EP EP06117339A patent/EP1752470B1/en not_active Not-in-force
- 2004-12-02 EP EP04801190A patent/EP1689775B1/en active Active
- 2004-12-02 SI SI200431747T patent/SI1689775T1/sl unknown
- 2004-12-02 NZ NZ547612A patent/NZ547612A/en not_active IP Right Cessation
- 2004-12-02 KR KR1020067013411A patent/KR101188785B1/ko not_active IP Right Cessation
- 2004-12-02 EP EP10174625A patent/EP2363411A1/en not_active Withdrawn
- 2004-12-02 ES ES04801190T patent/ES2369139T3/es active Active
- 2004-12-02 AU AU2004295104A patent/AU2004295104B2/en not_active Ceased
- 2004-12-02 BR BRPI0416544-6A patent/BRPI0416544A/pt not_active IP Right Cessation
- 2004-12-02 JP JP2006541888A patent/JP4980721B2/ja not_active Expired - Fee Related
- 2004-12-02 PT PT04801190T patent/PT1689775E/pt unknown
- 2004-12-02 DK DK06117339T patent/DK1752470T3/da active
- 2004-12-02 PT PT06117339T patent/PT1752470E/pt unknown
- 2004-12-02 CN CN200480036160.6A patent/CN1890264B/zh not_active Expired - Fee Related
- 2004-12-02 AT AT06117339T patent/ATE439376T1/de active
- 2004-12-02 ES ES06117339T patent/ES2330362T3/es active Active
- 2004-12-02 PL PL06117339T patent/PL1752470T3/pl unknown
- 2004-12-02 EP EP10180909A patent/EP2311866A1/en not_active Withdrawn
-
2006
- 2006-05-11 IL IL175565A patent/IL175565A0/en unknown
- 2006-06-05 US US11/422,169 patent/US7585937B2/en not_active Expired - Fee Related
-
2008
- 2008-06-02 US US12/131,311 patent/US7807413B2/en not_active Expired - Fee Related
-
2009
- 2009-05-07 US US12/437,121 patent/US20110144305A1/en not_active Abandoned
- 2009-10-08 CY CY20091101039T patent/CY1109480T1/el unknown
-
2010
- 2010-08-18 US US12/858,456 patent/US20100331237A1/en not_active Abandoned
-
2011
- 2011-09-16 CY CY20111100904T patent/CY1112330T1/el unknown
-
2012
- 2012-02-27 JP JP2012040123A patent/JP2012139226A/ja active Pending
- 2012-04-05 JP JP2012086483A patent/JP2012165747A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0416544A (pt) | proteìna de ligação de gag | |
BR0208207A (pt) | Redução da imunogenicidade das proteìnas de fusão | |
BR112012004697A2 (pt) | purificação melhorada de proteína através de uma eluição da proteína a modificada. | |
SG170116A1 (en) | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | |
WO1999006545A3 (en) | Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation | |
EP3660510A3 (en) | Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target | |
BR0211630A (pt) | Anticorpo, ácido nucleico isolado, vetores de expressão recombinantes, composição farmacêutica, método de inibição da atividade de tnfsf13b em um indivìduo sofrendo de um distúrbio no qual a atividade de tnfsf13b é prejudicial, uso do dito anticorpo, e, artigo de manufatura | |
BRPI0508096B8 (pt) | método de preparação de um preparado de anticorpo seguro purificado contra vírus e vírus inativado | |
BR0310099A (pt) | método para tratar dislipidemia ou uma doença associada com a dislipidemia | |
CO6231039A2 (es) | Composiciones que comprenden anticuerpo que se fija al dominio ii de her2 y sus variantes acidas | |
BR0209312A (pt) | Composição alimentìcia de isolado de proteìna de canola | |
BRPI0612840A8 (pt) | Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções | |
BRPI0810130A8 (pt) | Composição de bebida, processo para produzir uma composição de bebida, e, uso de uma composição de bebida | |
BRPI0514411B8 (pt) | formulação, e, método de produzir uma formulação | |
ATE485517T1 (de) | Verfahren zur identifizierung von polypeptid- targets | |
BRPI0519429A2 (pt) | composiÇço adequada para melhorar funÇço renal em um animal, mÉtodo para melhorar a funÇço renal em um animal, kit adequado para administrar composiÇÕes para melhorar a funÇço renal a um animal, meio para comunicar informaÇço, e, uso de uma composiÇço | |
DE602007014210D1 (de) | Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen | |
BR0014860A (pt) | Métodos para a produção de uma molécula alvo em um animal transgênico e purificação da molécula alvo | |
ATE529445T1 (de) | Biokinetik zur schnellen beseitigung von polypeptiden | |
BR0312521A (pt) | Métodos para a separação e a purificação de fibrinogênio e de pelo menos uma outra proteìna e para a co-purificação de fibrinogênio e de fator xiii, uso de cromatografia de afinidade com ìon de metal imobilizado, fibrinogênio, kit farmacêutico, e, formulações farmacêutica e de fibrinogênio liofilizado | |
EA200600539A1 (ru) | Способ определения воздействия многокомпонентной смеси естественных продуктов на биологический профиль заболевания в пределах группы живых систем и разработка и контроль качества лекарственных препаратов на основе естественных продуктов | |
WO2005086654A3 (en) | Self-cleaving affinity tags and methods of use | |
BR0308515A (pt) | Combinação de um antagonista de receptor de aldosterona com ácido nicotìnico ou um derivado de ácido nicotìnico | |
BRPI0507491A (pt) | métodos para melhorar as anormalidades da cartilagem em um animal e para impedir a degradação da cartilagem em um animal, e, composição para melhorar as anormalidades da cartilagem em um animal | |
BR0211130A (pt) | Plantas transgênicas que expressam proteìnas de ligação da cobalamina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |